ClinicalTrials.gg
RecruitingNCT06412185Updated Nov 8, 2024

Single Dose Escalation Study of CM383 in Healthy Volunteers

A Phase 1 interventional study of CM383 and Placebo in Alzheimer Disease, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to male participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
119th of 176
56 · median 100
Started
2024
with 40 others
Phase 1
26 of 260
18 open now
Primary completion
2025-06
later than 18 of 161 live
Registered
140th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 119th largest by planned enrollment of the 176 interventional ones that give a count, is one of 41 that started in 2024, is one of 26 in phase 1, reaches primary completion later than 18 of the 161 other live ones, and was the 140th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 18 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in male healthy subjects.

Read the detailed description

Alzheimer's disease (AD) is the most common type of dementia, which is a degenerative disease of the central nervous system with insidious onset and progressive development. Its clinical features mainly include memory impairment, cognitive impairment, psychobehavioral abnormalities, and social decline.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males, voluntarily participate;
  • 18 and 80 years old (including boundary values);
  • able to communicate well with the researchers and follow up the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • The average daily smoking volume within three months before screening is greater than 5 cigarettes;
  • Excessive alcohol consumption within three months before screening, or positive alcohol breath test;
  • Urine drug abuse screening is positive;
  • Having a family planning or sperm donation plan; Disagree to adopt efficient measures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Group 1

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

  • Experimental
    Group 2

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

  • Experimental
    Group 3

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

  • Experimental
    Group 4

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

  • Experimental
    Group 5

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

  • Experimental
    Group 6

    CM383 injection and matched placebo, intravenous injection

    Biological: CM383 · Other: Placebo

Interventions

  • BiologicalCM383

    CM383 Injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence of adverse events.

    Time frame: Up to week 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2025, 13 months after the start.

Of 162 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 13 months is close to that.

Counting every sponsor, half of 235 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
May 28, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06412185
Responsible party
Sponsor
First posted
May 14, 2024
Start date
May 28, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Nov 8, 2024

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Qing Wen
Contact
wenq0619@126.com
13370551767
Qing Wen
principal investigator · Jinan Central Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion